Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Feb;6(1):134-136.
doi: 10.21037/tau.2017.01.05.

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

David Dearnaley  1 , Emma Hall  2
Affiliations
Comment

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

David Dearnaley et al. Transl Androl Urol. 2017 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Prof. Dearnaley and Prof. Hall are Joint Principal Investigators (Prof. Dearnaley, Chief Investigator, Prof. Hall Statistical Lead) for the CHHiP Trial (Cancer Research UK; CRUK/06/016).

Comment on

References

    1. Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2016;17:1047-60. 10.1016/S1470-2045(16)30102-4 - DOI - PMC - PubMed
    1. Wilkins A, Mossop H, Syndikus I, et al. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 2015;16:1605-16. 10.1016/S1470-2045(15)00280-6 - DOI - PMC - PubMed
    1. Dearnaley D, Syndikus I, Sumo G, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. Lancet Oncol 2012;13:43-54. 10.1016/S1470-2045(11)70293-5 - DOI - PubMed
    1. Catton CN, Lukka H, Julian JA, et al. A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. J Clin Oncol 2016;34:abstr 5003.
    1. Incrocci L, Wortel RC, Alemayehu WG, et al. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2016;17:1061-9. 10.1016/S1470-2045(16)30070-5 - DOI - PubMed

LinkOut - more resources